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Available online 01 August 2016A gap in the knowledge on the status of heart failure (HF) in Asia versus other regions led to the creation of a
working group of Asian experts from 9 countries or regions (Hong Kong, Indonesia, Malaysia, Philippines,
Singapore, South Korea, Taiwan, Thailand, and Vietnam). Each expert sought the best available data from local
publications, registries, or clinical practice. The prevalence of HF in Asia was generally similar to global values
(1% to 3%), but with some outliers. There were substantial variations in healthcare spending, and the average
cost of HF hospitalization varied from 813 US$ in Indonesia to nearly 9000 US$ in South Korea. Comorbidities
were frequent, particularly hypertension, diabetes mellitus, and dyslipidemia. Modiﬁable risk factors such as
smoking were alarmingly common in some countries. Asian HF patients spent between 5 and 12.5 days in hos-
pital, and 3% to 15% were readmitted for HF by 30 days. The pharmacological treatment of Asian patients gener-
ally followed international guidelines, including renin–angiotensin–aldosterone system inhibitors (61% to 90%),
diuretics (76% to 99%), beta-blockers (32% to 78%), and digoxin (19% to 53%), with some room for improvement
in terms of life-saving therapies. Our review supports implementation of a more comprehensive and organized
approach to HF care in Asia.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Treatment1. Introduction
It is estimated that 38 million people worldwide have heart failure
(HF), with most published studies reporting a prevalence of between
1% and 2% of the adult population [1,2]. Data from Europe and North
America suggest that 1%–2% of all hospital admissions are related to
HF [3], amounting to more than 1 million admissions annually, with
80–90% being due to decompensation of chronic HF [4]. The syndrome
still carries a poor prognosis: 5% to 10% of patients die during hospital-
ization, with a further 15% dying by 3 months, and over half of patients
die within 5 years of their ﬁrst HF hospitalization [5]. Rates of rehospi-
talization are also high [4,6]. The ﬁnancial burden of HF, principally
due to the cost of hospitalization, is expected to increase substantially
in the coming decades due to the aging of the population worldwide
[7,8].land Ltd. This is an open access articlGlobally, the etiology of HFvaries, but hypertension and coronary ar-
tery disease (often associated with obesity and diabetes mellitus) ap-
pear to remain important, with valve disease, peripartum
cardiomyopathy, infection, and genetic causes being variably important.
Published studies suggest that the importance of coronary artery dis-
ease as a cause of HF worldwide is increasing [9], and particularly so
in Asia [10]. An increase in HF risk factors, such as obesity, hypertension,
and diabetes, related to changing lifestyles (“epidemiologic transition”)
in Asian countries is likely responsible for the rise in the prevalence of
HF [1,11]. However, the availability of data onHF burden and healthcare
delivery is limited compared with Europe and North America [12].
This gap in knowledge was the driver for the creation of a working
group of Asian experts in HF, whose objectives were to: (i) investigate
the current state of HF care in several Asian countries; and (ii) to foster
implementation of measures intended to improve the standard of HF
care in this region. We describe the currently available data on HFe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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those countries, summarizing available data on process and outcome
measures for HF care where available. We report data from Hong
Kong, Indonesia, Malaysia, Philippines, Singapore, South Korea,
Taiwan, Thailand, and Vietnam.
2. Methods
Each author contributed the most recently available data on HF care from their own
country, using what they considered to be the best available sources — ideally nationally
published data or where these were not available data from local or regional registries
or audit projects. Where possible, data were subdivided into HF with reduced ejection
fraction (HFREF) and other types of HF. Data were sought on the prevalence of HF, the
likely etiological factors, deaths, hospitalization duration and mortality, readmission
rates, overall cost of HF management, cost of drug therapy, and whether there were
local or national guidelines for HFmanagement. In addition, published data on the country
characteristics were collected (population, gross domestic product (GDP), growth,
healthcare expenditure as percentage of GDP, life expectancy, and cardiologists per coun-
try or per capita). For comparison purposes published data from Europe and North
America were also collected [2,3,13–26].
Published data were available for Hong Kong, Philippines, Singapore, South Korea,
Taiwan, Thailand, and Vietnam. There were two HF registries for Thailand: one registry
on all hospitalized HF (HFREF and other HF) [27] and another for HFREF only [28]. The
data from the Philippines also included data from ﬁve major hospital centers [29], while
those from Indonesia include data from one hospital based on experience since 2009.
The data from Vietnam were collected at the Hanoi Heart Hospital from August 2014 to
February 2015. The data fromMalaysia included all admissions due to acute HF registered
in the Institut Jantung Negara (the Malaysian National Heart Institute) acute decompen-
sated HF registry since 2009.
3. Results
General socioeconomic and health expenditure data for the region
are presented in Fig. 1 [13,14,17]. The populations of the nine participat-
ing Asian countries varied greatly in size from Singapore (5.7million) to
Indonesia (256 million). The wealth of the countries also varied mark-
edly, ranging from a GDP per capita of 2230 US$ in Vietnam to 58,910
US$ in Singapore. As a percentage of GDP, South Korea spent the mostVietnam
•  91.4 / 72.9 / 29.6
•  2,230 / +6.6%
•  12.0 / 5.9%
Indonesia
•  255.8 / 72.2
•  3,870  / +5.9
•  27.4 / 2.8%
Singapore
•  5.7 / 84.4 / 34.0
•  58,910 / +3.8%
•  15.4 / 4.6%
Malaysia
•  30.7 / 74.5 / 27.9
•  12,090 / +5.4%
•  13.7 / 3.7%
Thailand
•  67.4 / 74.2 / 36.7
•  6,260 / +4.5%
•  15.5 / 3.9%
Population (million)/life expectancy*/mean age* − GDP per capita (USD) / GDP
* CIA World Fac
Fig. 1. National characteristics in nine Asian counton healthcare (6.7%) though this was still substantially lower than
Europe and the USA. Four countries (Indonesia, Vietnam, Thailand,
and the Philippines) spent more than 20% of their healthcare budgets
on pharmaceuticals. The average published cost of HF hospitalization
varied from 813 US$ in Indonesia to nearly 9000 US$ in South Korea.
The number of cardiologists in each country for which data were avail-
able were: Hong Kong 228 (32 per million of population), the
Philippines 1400 (14 per million), Singapore 229 (40 per million),
Taiwan 1637 (70 per million), Vietnam 2000 (21 per million), and
USA 27,076 (84 per million).
Of the countries for which data were available, the prevalence of
HF (1% to 3%)was generally similar to values reported for Europe and
the literature value of 0.9% in China [30], though values N5% were
reported from Indonesia and Taiwan (Table 1) [2,3,20,22–29,
31–34]. The prevalence was reported as higher in men than
women, but Asian HF patients appeared to be slightly younger than
their European and American counterparts, reﬂecting the generally
younger demographic of these countries. The reported etiologies of
HF are also presented in Table 1: ischemic heart disease was the
most common cause of HF in all countries except Hong Kong,
where hypertensive heart disease was the most common cause
(70% versus 29% for ischemic heart disease).
Vascular risk factors such as hypertension, diabetes mellitus, and
dyslipidemia were common in HF patients in all countries (Table 1),
but particularly so in Malaysia (75%, 67%, and 52%, respectively) and
Singapore (69%, 55%, and 65%, respectively). Smoking was frequent,
with high reported rates in some countries, most notably the
Philippines (54%) and Vietnam (31%). Rates of renal disease ranged
from 4% in the Philippines to 31% in Taiwan. Roughly a ﬁfth of patients
had concomitant atrial ﬁbrillation and more than a tenth had chronic
obstructive pulmonary disease or asthma.
Available data on hospitalizations for HF and associated mortality
are presented in Table 2 [3,20,22,23,35–38]. The country with the
highest number of HF hospitalizations was Taiwan, with 40,000South Korea
•  50.8 / 79.8 / 40.8
•  30,110  / +3.7%
•  102.6 / 6.7%
Taiwan
•  23.5 / 79.8 / 39.7
•  22,700 / +3.3%
•  33.5 / 6.3%
Hong Kong
•  7.1 / 82.8 / 43.6
•  41,990  / +2.6%
•  16.8 / 5.6%
Philippines
•  101.8 / 72.5 / 23.2
•  3,260 / +6.3%
•  13.8 / 4.2%
 / 29.6
%
 growth (per annum) − Health expenditure total (billion USD) / % of GDP 
tbook 2015
ries [13,14,17]. GDP, gross domestic product.
Table 1
Prevalence of heart failure (HF), demographic characteristics of patients and etiology in 9 Asian countries or regions, and Europe and the USA [2,3,20,22–29,31–34].
Prevalence or characteristic Asia Europe USA
Hong Kong Indonesia Malaysia Philippines Singapore South Korea Taiwan Thailand Vietnam
Prevalence of HF 2%–3%a 5% – 1%–2% – 0.6% 6% 0.4% – 1%–2% 2%
Demographic characteristics of HF patients
Male 45% 66% 75% 57% 64% 55% 72% – 59% 61% 53%
Female 55% 34% 26% 43% 36% 45% 28% – 41% 39% 47%
Mean age at admission (years) 76.8 57.8 61.8 60 66.6 69 64 67 59 70 74
Cardiovascular risk factors
Ischemic heart disease 29% 35% 68% 52% 37% 37% 44% 45% 32% 54% 46%
Valvular/rheumatic heart disease 6% 18% 29% 20% – 14% 8% 19% 18% – –
Cardiomyopathy (non-ischemic) 1% 2% 28% 11% – 21% 34% 14% 21% – –
Hypertensive heart disease 70% 8% 2% 6% – 4% 7% 12% 21% – 23%
Other causesb 2% 5% 7% – 11% 7% – – – –
Hypertension 33% 75% 64% 69% 33% 31% – 63% 76%
Current smoking 13% 28% 9% 54% 45% 24% 7% 31% – –
Diabetes mellitus 36% 37% 67% 41% 55% 43% 47% – 33% 43%
Dyslipidemia 31% 52% 38% 65% 24% 51% 5% – 44%
Overweight 47% 25% 21% – – – – – –
Renal disease 24% 31% 4% – 31% 19% 5% 17% 50%
Atrial ﬁbrillation 16% 24% – 21% 26% 24% 22% 39% 31%
Coronary heart disease 35% 73% 52% 49% 43% 47% – 54% 50%
Cerebrovascular disease 2% 7% 0% 15% 9% 12% – – –
COPD 18% 13% 2% 12% 12% 8%c 3% 19% –
Missing data are not available.
a In patients aged N85 years.
b Including tachycardia, congenital heart disease and cardiopulmonary heart disease.
c COPD or asthma.
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than a ﬁfth of total hospitalizations (19% in Thailand). Rates of readmis-
sion ranged between 3% and 15% at 30 days. AsianHF patients spent be-
tween 5 days (Indonesia) and 12.5 days (Taiwan) in hospital,
comparable with the range seen across North America and Europe.
The rate of in-hospital mortality was also similar to values reported in
Europe and the USA. The reported rates of mortality at 30 days varied
from 1% in Malaysia to 17% in Indonesia (though the exact reasons for
this discrepancy remain unclear).
The pharmacological treatment of Asian patients with HF followed
closely the management strategies laid out in the North American and
European guidelines (Table 3) [35,39], which are viewed as sources of
professional guidance in all of the countries in our survey. Renin-
angiotensin-aldosterone system (RAAS) inhibitors were widely pre-
scribed (from 61% in Taiwan to 90% in Vietnam), more often as ACE in-
hibitors than angiotensin II receptor blockers. The majority of patients
received diuretics (76% to 99%). Beta-blockers (32% to 78%) and digoxin
(19% to 53%) were also prescribed, though less frequently. National HF
(professional) guidelines for the management of HF were available in
most countries: Indonesia, Singapore, Taiwan, Thailand, and Vietnam,
and are in preparation in South Korea and the Philippines. Currently,Table 2
Heart failure (HF) hospitalization and mortality in the 9 Asian countries or regions, and Europe
Hospitalization characteristics Asia
Hong Kong Indonesia Malaysia Philippines
Hospitalizations
HF hospitalizations per year 18,000 – – –
% of total hospitalizations – – – 9%
Readmission rate
By 30 days – 7% 8% –
Hospital stay
Mean (days) 6–10 5 9.24 10
Median (range) (days) – 5 7 (4–11) 7 (1–133)
Mortality
Inpatient – 3% 6% 7%
Within 30 days of discharge – 17% 1% 10%
Annual cost of HF (US$ million)
Cost of hospitalization (US$ per pt) 2916–4860 813 – –
Missing data are not available.there are none in Hong Kong. Only Thailand and South Korea had a na-
tional society devoted to HF. A national HF registry has been set up in
Singapore with metrics to evaluate the management of HF on both the
hospital and the national level.
4. Discussion
Although our report includes nine varied Asian countries with a
wide range of economic wealth and demographic differences, the avail-
able data clearly show that HF is a major healthcare problem across the
region. In general the etiological factors appear very similar to those re-
ported in Europe and North America with a high prevalence of HF of is-
chemic origin, pointing towards a westernization of lifestyle in our
countries as it has been documented in China and India [40,41]. Coro-
nary heart disease, dyslipidemia, and diabetes mellitus were frequent
in our survey, and are probably related to lifestyle changes character-
ized by a decrease in physical activity and a higher calorie/fat intake
[42]. Hospital practice also appears similar in terms of length of stay
and mortality to most published data, and high readmission rate is
also noted. In contrast with Europe and North America, there are few
national professional societies for HF, and few systematic registries orand the USA [3,20,22–24,35–38].
Europe USA
Singapore South Korea Taiwan Thailand Vietnam
6000 – 40,000 – – – N1M
– – 2.2% 19% 15% – –
17.6% (90 days) – 3%–15% – 7% – 25%
5.1 – 12.5 7.5 8.7 – –
– 8 8 (1–148) – 9 (2–30) 8 5
1.1% 6.1% – 6% 7% 6% 4%
– – – – 2%–3% – 10%
– 8887 2388 3606 1000 – 23,077
Table 3
Pharmacological treatment of HF in 9 Asian countries or regions, and Europe and the USA [26,28,35,39].
Pharmacological treatment of HF Asia Europe USA
Hong Kong Indonesia Malaysia Philippines Singapore South Korea Taiwan Thailand Vietnam
RAAS inhibitor 52% 78% 67% 70% 74% 65% 61% 77% 90% 89% 66%
Beta-blocker 39% 32% 72% 38% 65% 44% 57% 78% 41% 87% 81%
Calcium channel blocker – – 17% 12% – 12% – – 10% –
Ivabradine – – – 0% – – 6% 21% – –
Diuretic 84% 78% 99% 76% 87% 80% 92% – 83% –
Digoxin 11% 21% 44% 53% 27% 26% – 19% 21% –
Lipid-lowering agent – – 76% – 72% – – – 54% 62%
Anticoagulant – – 25% 26% 12% 20% – 30% 43% 65%
Missing data are not available.
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based on international guidelines.
There appears to be much room for improvement in terms of physi-
cian adherence to national and international clinical practice guidelines,
as shown by the low rate of beta-blockers use in some countries
(e.g., Indonesia and the Philippines). Indeed, few patients appear to re-
ceive simultaneously all four drugs shown to improve outcome for pa-
tients with HFREF (ACE inhibitor, beta-blocker, mineralocorticoid
receptor antagonist, and for those in sinus rhythm, ivabradine). Efforts
to monitor and improve identiﬁcation of patients for such therapies
are likely to improve patient outcome and also reduce healthcare ex-
penditure (by reducing hospitalization rates) [43].
The authors are aware that post-discharge follow up for HF
patients is relatively rare in the countries represented in this survey.
Initiatives for patient and family education are also scarce, as shown
by the limited number of specialized HF care centers (e.g., in
Indonesia, which covers a huge geographical area consisting of
many islands). It is likely that efforts to improve transitional care
and patient education, as recommended in the most recent North
American and European guidelines, would improve readmission
rates and long-term compliance with life-saving therapy. This is
likely to be a particular challenge in countries with a low GDP per
capita, and without a national professional society to lobby for an
increased focus on HF at the local and national levels. Delivering
care across complex geographies is also likely to be challenging.
The large variation in the sources of collected data is the main limi-
tation of our report. We endeavored to report the best available data
based on national or regional surveys, and succeeded to do so in most
countries. For Indonesia, Vietnam, and Malaysia, data originate from
single hospital center and may not be generalizable to the whole coun-
try, especially when they arise from highly specialized center such as
the Hanoi Heart Hospital. However, in the absence of national or re-
gional registries in these countries, the reliability of single hospital-
based estimates remains difﬁcult to establish. We hope that this publi-
cation may help foster such initiatives and highlight the need for good
data to drive quality improvement initiatives, such as has been seen in
the USA (Get with the Guidelines, American Heart Association) and
theUK (National HFAudit andNational Institute for Health and Care Ex-
cellence Guidelines and Quality Standards) [44–46].
The authors of this report have set up a task force to help foster a
more comprehensive and organized approach to HF care in their region.
This includes initiatives to optimize prescription of appropriate drug
therapies by the introduction of hospital protocols and checklists, im-
proving patient education using a patient passport and a smart phone
Application, and upskilling non-cardiologists (including HF nurses) in
the follow-up of patients after discharge from hospital. The impact of
such initiatives will be reported in a future publication.Conﬂicts of interest
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